What are the functions and efficacy of pemetinib/pemetinib?

Pemetinib is a potent and selective oral inhibitor of fibroblast growth factor receptor (FGFR) subtype1/2/3. It reduces cell viability by inhibiting the phosphorylation and signaling of FGFR, thereby inhibiting the proliferation of tumor cells. Specifically, the mechanism of action of pemetinib mainly includes the following aspects:

1.Inhibition of FGFR activity: FGFR is an important receptor tyrosine kinase that participates in many cell growth and proliferation processes. However, in certain types of tumors such as cholangiocarcinoma, the activity of FGFR is excessively enhanced, leading to abnormal proliferation and spread of tumor cells. Pemetinib can selectively bind to FGFR and inhibit its activity, thereby preventing the growth and spread of tumor cells.

2.Blocking signaling: Pemetinib blocks the activation of downstream signaling pathways by inhibiting the phosphorylation ofFGFR. This results in the suppression of the expression of a series of genes related to tumor growth, survival, migration and angiogenesis, further inhibiting tumor development.

3.Multi-target inhibitory effect: In addition to its main effect on FGFR, pemetinib may also inhibit other targets related to tumor growth and spread. This multi-target mechanism of action gives pemetinib a broader anti-tumor effect.

Pemetinib has shown significant efficacy in treating certain types of cancer, such as cholangiocarcinoma. The following are several aspects of its main functions:

1.Inhibiting tumor growth: Pemetinib can effectively inhibit the growth of tumors such as cholangiocarcinoma. An open-label Phase II clinical trial showed that after patients received pemetinib treatment, the overall effective rate reached 36.0%, of which 11.2% patients achieved partial response, and 24.8%The patient's disease was stabilized. This result brings new hope for the treatment of patients with cholangiocarcinoma.

2.Prolong survival: Pemetinib can not only inhibit tumor growth, but also significantly extend the survival of patients with cholangiocarcinoma. An open-label clinical trial of patients with cholangiocarcinoma with FGFR2 gene abnormalities showed that patients treated with pemetinib had a median progression-free survival of 6.9 months, compared with 1.8 months for patients who received conventional chemotherapy. This means that pemetinib treatment can significantly extend the survival time of patients with cholangiocarcinoma and provide them with more treatment opportunities.

3.Good safety: Although pemetinib has shown good efficacy in the treatment of tumors such as cholangiocarcinoma, its safety has also been fully verified. In clinical studies, the side effects of pemetinib are relatively mild and mostly reversible. Common side effects include fatigue, nausea, vomiting, diarrhea, loss of appetite, etc., while serious side effects such as high blood pressure and liver damage are rare. Therefore, the safety of pemetinib in clinical application has been widely recognized.

Pemetinib has been widely used in the treatment of certain types of cancer, such as cholangiocarcinoma. Its indications mainly include:

1.Cholangiocarcinoma: Indicated for the treatment of adults with previously treated unresectable locally advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (fgfr 2) fusion or other rearrangement detected by an FDA-approved test.

2.Myeloid neoplasms with FGFR1 rearrangements/Lymphoid neoplasms: Pemetinib is indicated for the treatment of patients with fibroblast growth factor receptor1 (FGF Adults with relapsed or refractory myeloid /lymphoid neoplasms (MLNs) rearranged with R1.